|Bid||301.00 x 900|
|Ask||0.00 x 800|
|Day's Range||296.31 - 301.58|
|52 Week Range||223.25 - 468.55|
|Beta (5Y Monthly)||0.39|
|PE Ratio (TTM)||23.87|
|Earnings Date||Oct. 19, 2021 - Oct. 25, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||417.70|
In the latest trading session, Biogen Inc. (BIIB) closed at $298.49, marking a -0.57% move from the previous day.
The CHMP gives a positive opinion on, and recommends granting marketing authorization to Biogen's (BIIB) Vumerity for the treatment of adults with relapsing-remitting multiple sclerosis.
BYOOVIZ™ becomes the first ophthalmology biosimilar to gain FDA approval in the United States INCHEON, Korea and CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i, for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occ